WO2024018423 - PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS
National phase entry:
Publication Number
WO/2024/018423
Publication Date
25.01.2024
International Application No.
PCT/IB2023/057419
International Filing Date
20.07.2023
Title **
[English]
PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS
[French]
PYRROLES ET IMIDAZOLES UTILISÉS COMME INHIBITEURS DE PROTÉINES BET
Applicants **
TAY THERAPEUTICS LIMITED
Inventors
BELL, Mark
FOLEY, David William
WOODLAND, Christopher Andrew
Priority Data
2210714.8
21.07.2022
GB
2302871.5
27.02.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5451 | |
| EPO | Filing, Examination, Granting | 34376 | |
| Japan | Filing, Examination, Granting | 3226 | |
| South Korea | Filing, Examination, Granting | 4182 | |
| USA | Filing, Examination, Granting | 12790 |
Total:
60,025
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure relates to compounds of formula (I) comprising a pyrrole or imidazole core, and pharmaceutically acceptable salts and compositions of such compounds. The compounds disclosed are useful as anti-inflammatory and/or other therapies.[French]
L'invention concerne des composés de formule (I) comprenant un noyau pyrrole ou imidazole, et des sels pharmaceutiquement acceptables et des compositions de ces composés. Les composés de l'invention sont utiles en tant que thérapies anti-inflammatoires et/ou autres.